{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T01:20:30Z","timestamp":1648862430888},"reference-count":28,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.3892\/ol.2011.398","type":"journal-article","created":{"date-parts":[[2011,8,29]],"date-time":"2011-08-29T03:11:24Z","timestamp":1314587484000},"page":"1033-1040","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy"],"prefix":"10.3892","volume":"2","author":[{"given":"TOSHIAKI","family":"TAKAHASHI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NOBUYUKI","family":"YAMAMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOHIDE","family":"TAMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIDEO","family":"KUNITOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUTAKA","family":"NISHIWAKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHUNICHI","family":"NEGORO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2011,8,29]]},"reference":[{"key":"key20180108093601_b1-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1008296622469","article-title":"Recombinant human erythropoietin in the treatment of chemotherapy induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study","volume":"9","author":"Oberhoff","year":"1998","journal-title":"Ann Oncol"},{"key":"key20180108093601_b2-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy; results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20180108093601_b3-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"key20180108093601_b4-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"N Engl J Med"},{"key":"key20180108093601_b5-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phases I and II clinical trial","volume":"316","author":"Eshbach","year":"1987","journal-title":"N Engl J Med"},{"key":"key20180108093601_b6-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","article-title":"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production","volume":"122","author":"Cazzola","year":"2003","journal-title":"Br J Haematol"},{"key":"key20180108093601_b7-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1634\/theoncologist.10-8-642","article-title":"Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy","volume":"10","author":"Waltzman","year":"2005","journal-title":"Oncologist"},{"key":"key20180108093601_b8-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djj053","article-title":"Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia","volume":"98","author":"Canon","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"key20180108093601_b9-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1517\/13543784.16.10.1649","article-title":"C.E.R.A. pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease","volume":"16","author":"Locatelli","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180108093601_b10-ol-02-06-1033","first-page":"769A(Abstract SU-PO 1063)","article-title":"CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life","volume":"14","author":"Macdougall","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key20180108093601_b11-ol-02-06-1033","first-page":"436","article-title":"CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia","volume":"4","author":"Macdougall","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"key20180108093601_b12-ol-02-06-1033","first-page":"748(Abstract 3006)","article-title":"Pre-clinical and Phase I pharmacokinetic and mode-of-action studies of CERA (Continuous Erythropoiesis Receptor Activator), an innovative erythropoietic agent with an extended serum half-life","volume":"22","author":"Haselbeck","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"key20180108093601_b13-ol-02-06-1033","first-page":"iii157(Abstract 592)","article-title":"Continuous Erythropoiesis Receptor Activator (CERA) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers","volume":"15","author":"Dougherty","year":"2004","journal-title":"Ann Oncol"},{"key":"key20180108093601_b14-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3324\/haematol.10730","article-title":"A dose exploration, phase I\/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy","volume":"92","author":"Dmoszynska","year":"2007","journal-title":"Haematologica"},{"key":"key20180108093601_b15-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2141.2007.06494.x","article-title":"Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anemic patients with aggressive non-Hodgkin\u2019s lymphoma receiving combination chemotherapy","volume":"136","author":"Osterborg","year":"2007","journal-title":"Br J Haematol"},{"key":"key20180108093601_b16-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-8-8","article-title":"Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoiesis Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy","volume":"8","author":"Hirsh","year":"2007","journal-title":"Trials"},{"key":"key20180108093601_b17-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin \u03b2, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"key20180108093601_b18-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0169-5002(02)00275-1","article-title":"Anemia and lung cancer","volume":"38","author":"Crawford","year":"2002","journal-title":"Lung Cancer"},{"key":"key20180108093601_b19-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.10712","article-title":"Standards of care for anemia management in oncology; focus on lung carcinoma","volume":"95","author":"Langer","year":"2002","journal-title":"Cancer"},{"key":"key20180108093601_b20-ol-02-06-1033","first-page":"43","article-title":"Factors influencing quality of life in cancer patients: anemia and fatigue","volume":"25","author":"Cella","year":"1998","journal-title":"Semin Oncol"},{"key":"key20180108093601_b21-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3816\/CLC.2003.n.022","article-title":"Anemia in lung cancer: clinical impact and management","volume":"5","author":"Pirker","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"key20180108093601_b22-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2004.04.034","article-title":"Role of epoetin in the management of anemia in patients with lung cancer","volume":"46","author":"Mor\u00e8re","year":"2004","journal-title":"Lung Cancer"},{"key":"key20180108093601_b23-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"key20180108093601_b24-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/jjco\/hyl074","article-title":"Pharmacokinetics and Pharmacodynamics of Weekly Epoetin Beta in Lung Cancer Patients","volume":"36","author":"Fujisaka","year":"2006","journal-title":"Jpn J Oncol"},{"key":"key20180108093601_b25-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2482\/haigan.47.313","article-title":"Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics\/Pharmacodynamics Study","volume":"47","author":"Nakagawa","year":"2007","journal-title":"Jpn J Lung Cancer"},{"key":"key20180108093601_b26-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/jps.20125","article-title":"Pharmacokinetic aspects of biotechnology products","volume":"93","author":"Tang","year":"2004","journal-title":"J Pharm Sci"},{"key":"key20180108093601_b27-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ejca.2005.01.021","article-title":"Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa","volume":"41","author":"Glaspy","journal-title":"Eur J Cancer"},{"key":"key20180108093601_b28-ol-02-06-1033","doi-asserted-by":"crossref","first-page":"E552","DOI":"10.1208\/aapsj080364","article-title":"Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy","volume":"8","author":"Agoram","year":"2006","journal-title":"AAPS J"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2011.398\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T06:04:20Z","timestamp":1515391460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2011.398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,29]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,8,29]]},"published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.3892\/ol.2011.398"],"URL":"https:\/\/doi.org\/10.3892\/ol.2011.398","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,29]]}}}